Summary
Ecolab Inc. (ECL) filed an 8-K on April 7, 2017, primarily to provide investors with supplemental unaudited financial information. This filing includes revised segment net sales and operating income data for the years ended December 31, 2016, and December 31, 2015. The adjustments reflect international operations at fixed currency exchange rates established at the beginning of 2017, and the creation of a new 'Life Sciences' operating segment. These changes are intended to better align with the company's strategic growth initiatives, particularly in pharmaceutical and personal care manufacturing.
Key Highlights
- 1Supplemental financial data provided for 2016 and 2015 segment net sales and operating income.
- 2Adjustments made to reflect international operations at fixed currency exchange rates (2017 rates).
- 3Introduction of a new 'Life Sciences' operating segment effective Q1 2017.
- 4The new segment is designed to support growth in pharmaceutical and personal care manufacturing operations.
- 5Immaterial changes to customer allocations and cost distributions between segments are also reflected.
- 6This information is supplemental and does not replace previously filed financial statements (10-Q, 10-K).
- 7Information furnished is not deemed 'filed' under Section 18 of the Exchange Act, limiting liability.
Frequently Asked Questions
The primary purpose of this 8-K filing is to provide investors with supplemental, unaudited financial information regarding Ecolab's operating segments. This includes adjusted net sales and operating income for 2015 and 2016, reflecting a new way of presenting international results and the creation of a new business segment.
The key changes involve presenting international operations at fixed currency exchange rates (set at the beginning of 2017) and establishing a new 'Life Sciences' operating segment. There are also minor adjustments for customer and cost reallocations between segments.
The 'Life Sciences' operating segment is being established to better align with Ecolab's strategy for growth in its pharmaceutical and personal care manufacturing operations.
No, this information is supplemental and is not intended to replace the financial data reported in Ecolab's previously filed Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.